RWS of Inetetamab HER2 Positive Advanced Breast Cancer
- Conditions
- HER2-positive Advanced Breast Cancer
- Interventions
- Registration Number
- NCT04963608
- Lead Sponsor
- Zhiyong Yu
- Brief Summary
This non-Interventional study will describe and analyze the clinical use of Inetetamab in clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
- Patients with stage IV breast cancer
- Patients with HER2 positive status
- Patients that received Inetetamab
- Patients that began Inetetamab therapy prior to June 30, 2021.
Exclusion Criteria
Patients treated with an investigational anticancer agent Inetetamab
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description non-interventional study Inetetamab Her2 positive ABC patients who have received Inetetamab in the metastatic setting.
- Primary Outcome Measures
Name Time Method Progression Free Survival(PFS) 12 months Incidences of adverse events and toxicities 12 months
- Secondary Outcome Measures
Name Time Method